Breast Cancer Prevention Trials Using Retinoids

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.

Original languageEnglish
Pages (from-to)19-30
Number of pages12
JournalJournal of Mammary Gland Biology and Neoplasia
Volume8
Issue number1
DOIs
Publication statusPublished - Jan 2003

Fingerprint

Fenretinide
Retinoids
Breast Neoplasms
Carcinogenesis
Breast
Biomarkers
Second Primary Neoplasms
Cytoplasmic and Nuclear Receptors
Secondary Prevention
Insulin-Like Growth Factor I
Ovarian Neoplasms
Toxicology
Pharmacokinetics
Clinical Trials
Ligands
Safety
Pharmaceutical Preparations

Keywords

  • Breast neoplasms
  • Chemoprevention
  • Clinical trial
  • Fenretinide
  • Retinoids

ASJC Scopus subject areas

  • Cancer Research

Cite this

@article{0ebe3073d2f247e8a8a2ae5744ff823a,
title = "Breast Cancer Prevention Trials Using Retinoids",
abstract = "Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.",
keywords = "Breast neoplasms, Chemoprevention, Clinical trial, Fenretinide, Retinoids",
author = "Andrea Decensi and Davide Serrano and Bernardo Bonanni and Massimiliano Cazzaniga and Aliana Guerrieri-Gonzaga",
year = "2003",
month = "1",
doi = "10.1023/A:1025779120649",
language = "English",
volume = "8",
pages = "19--30",
journal = "Journal of Mammary Gland Biology and Neoplasia",
issn = "1083-3021",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Breast Cancer Prevention Trials Using Retinoids

AU - Decensi, Andrea

AU - Serrano, Davide

AU - Bonanni, Bernardo

AU - Cazzaniga, Massimiliano

AU - Guerrieri-Gonzaga, Aliana

PY - 2003/1

Y1 - 2003/1

N2 - Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.

AB - Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated because of its favorable toxicological profile in humans. In a phase III secondary prevention trial, fenretinide showed a trend to a reduction of second breast malignancies in premenopausal women but not in postmenopausal women. This pattern was associated with a similar modulation of circulating IGF-I. A trend towards a reduction of ovarian cancer was also noted. Biomarker studies of fenretinide or novel selective retinoids alone and in combination with different nuclear receptor ligands are being conducted. These studies provide a model for testing the safety and tolerability, pharmacokinetics and pharmacodynamics, and biomarker modulation in high-risk women, and offer clues as to both the pathophysiology of carcinogenesis and the drug mechanisms of action, and help select new compounds and doses for testing in large randomized studies.

KW - Breast neoplasms

KW - Chemoprevention

KW - Clinical trial

KW - Fenretinide

KW - Retinoids

UR - http://www.scopus.com/inward/record.url?scp=1642441732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642441732&partnerID=8YFLogxK

U2 - 10.1023/A:1025779120649

DO - 10.1023/A:1025779120649

M3 - Article

C2 - 14587861

AN - SCOPUS:1642441732

VL - 8

SP - 19

EP - 30

JO - Journal of Mammary Gland Biology and Neoplasia

JF - Journal of Mammary Gland Biology and Neoplasia

SN - 1083-3021

IS - 1

ER -